Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

pATM and γH2AX are effective radiation biomarkers in assessing the radiosensitivity of 12C6+ in human tumor cells

Authors: Jin Zhao, Zhong Guo, Shuyan Pei, Lei Song, Chenjing Wang, Jianxiu Ma, Long Jin, Yanqing Ma, Renke He, Jianbin Zhong, Ying Ma, Hong Zhang

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

Tumour radiosensitivity would be particularly useful in optimizing the radiation dose during radiotherapy. The aim of the current study was to evaluate the potential value of phosphorylated H2AX (γH2AX) and ATM (pATM) in assessing 12C6+ radiosensitivity of tumour cells.

Methods

Human cervical carcinoma HeLa cells, hepatoma HepG2 cells, and mucoepidermoid carcinoma MEC-1 cells were irradiated with different doses of 12C6+. The survival fraction was assayed with clonogenic survival method and the foci of γH2AX and pATM was visualized using immunocytochemical methods. Flow cytometry was used to assay γH2AX, pATM and the cell cycle.

Results

The survival fraction decreased immediately in dose-dependent manner, but in turn, significantly increased during 24 h after 12C6+ irradiation. Both γH2AX and pATM foci accumulated linearly with doses and with a maximum induction at 0.5 h for γH2AX and 0.5 or 4 h for pATM, respectively, and a fraction foci kept for 24 h. The expression of γH2AX and pATM was in relation to cell cycle. The G0/G1 phase cells had the highest expression of γH2AX after 0.5 h irradiation and then decreased to a lower level at 24 h after irradiation. An obvious increase of pATM in G2/M phase was shown after 24 h of 2 and 4 Gy irradiation. The significant G2/M phase arrest was shown. There was a close relationship between the clonogenic survival and γH2AX and pATM expression both in timing and dose in response to 12C6+.

Conclusions

The rate of γH2AX and pATM formation and loss may be an important factor in the response of cells to 12C6+. pATM and γH2AX are effective radiation biomarkers in assessing the radiosensitivity of 12C6+ in human tumor cells.
Literature
1.
Okayasu R. Repair of DNA damage induced by accelerated heavy ions-a mini review. Int J Cancer. 2012;130:991–1000.CrossRefPubMed
2.
Lorat Y, Brunner CU, Schanz S, et al. Nanoscale analysis of clustered DNA damage after high-LET irradiation by quantitative electron microscopy–the heavy burden to repair. DNA Repair (Amst). 2015;28:93–106.CrossRefPubMed
3.
Takahashi M, Hirakawa H, Yajima H, et al. Carbon ion beam is more effective to induce cell death in sphere-type A172 human glioblastoma cells compared with X-rays. Int J Radiat Biol. 2014;90:1125–32.CrossRefPubMed
4.
Gerelchuluun A, Manabe E, Ishikawa T, et al. The major DNA repair pathway after both proton and carbon-ion radiation is NHEJ, but the HR pathway is more relevant in carbon ions. Radiat Res. 2015;183:345–56.CrossRefPubMed
5.
Horn S, Brady D, Prise K. Alpha particles induce pan-nuclear phosphorylation of H2AX in primary human lymphocytes mediated through ATM. Biochim Biophys Acta. 2015;1853((10 Pt A)):2199–206.CrossRefPubMed
6.
Meyer B, Voss KO, Tobias F, et al. Clustered DNA damage induces pan-nuclear H2AX phosphorylation mediated by ATM and DNA-PK. Nucleic Acids Res. 2013;41:6109–18.CrossRefPubMedPubMedCentral
7.
Turinetto V, Giachino C. Multiple facets of histone variant H2AX: a DNA double-strand-break marker with several biological functions. Nucleic Acids Res. 2015;43:2489–98.CrossRefPubMedPubMedCentral
8.
Larsen DH, Stucki M. Nucleolar responses to DNA double-strand breaks. Nucleic Acids Res. 2016;44:538–44.CrossRefPubMed
9.
Lorat Y, Timm S, Jakob B, et al. Clustered double-strand breaks in heterochromatin perturb DNA repair after high linear energy transfer irradiation. Radiother Oncol. 2016;121:154–61.CrossRefPubMed
10.
Nickoloff JA. Photon, light ion, and heavy ion cancer radiotherapy: paths from physics and biology to clinical practice. Ann Transl Med. 2015;3(21):336.PubMedPubMedCentral
11.
Xue L, Furusawa Y, Okayasu R, et al. The complexity of DNA double strand break is a crucial factor for activating ATR signaling pathway for G2/M checkpoint regulation regardless of ATM function. DNA Repair (Amst). 2015;25:72–83.CrossRef
12.
Xue L, Furusawa Y, Yu D. ATR signaling cooperates with ATM in the mechanism of low dose hypersensitivity induced by carbon ion beam. DNA Repair (Amst). 2015;34:1–8.CrossRefPubMed
13.
Xue L, Yu D, Furusawa Y, et al. Regulation of ATM in DNA double strand break repair accounts for the radiosensitivity in human cells exposed to high linear energy transfer ionizing radiation. Mutat Res. 2009;670:15–23.CrossRefPubMed
14.
Zhao J, Guo Z, Zhang H, et al. The potential value of the neutral comet and γH2AX foci assays in assessing radiosensitivity to carbon ion beams radiation therapy in human tumor cell lines. Radiol Oncol. 2013;47:247–57.CrossRefPubMedPubMedCentral
15.
Banuelos CA, Banáth JP, MacPhail SH, et al. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin Cancer Res. 2007;13(22 Pt 1):6816–26.CrossRefPubMed
16.
Takahashi A, Yamakawa N, Kirita T, et al. DNA damage recognition proteins localize along heavy ion induced tracks in the cell nucleus. J Radiat Res. 2008;49:645–52.CrossRefPubMed
17.
Schmid TE, Dollinger G, Beisker W, et al. Differences in the kinetics of gamma-H2AX fluorescence decay after exposure to low and high LET radiation. Int J Radiat Biol. 2010;86:682–91.CrossRefPubMed
18.
Guo Z, Zhao J, Song L, et al. Induction of H2AX phosphorylation in tumor cells by gossypol acetic acid is mediated by phosphatidylinositol 3-kinase (PI3 K) family. Cancer Cell Int. 2014;14:141.CrossRefPubMedPubMedCentral
19.
Loignon M, Amrein L, Dunn M, Aloyz R. XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death. Cell Cycle. 2007;6:606–11.CrossRefPubMed
20.
Maser RS, Monsen KJ, Nelms BE, Petrini JH. hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks. Mol Cell Biol. 1997;17:6087–96.CrossRefPubMedPubMedCentral
21.
Siddiqui MS, François M, Fenech MF, Leifert WR. γH2AX responses in human buccal cells exposed to ionizing radiation. Cytom A. 2015;87:296–308.CrossRef
22.
Bekker-Jensen S, Lukas C, Kitagawa R, et al. Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. J Cell Biol. 2006;173:195–206.CrossRefPubMedPubMedCentral
23.
Nambiar DK, Rajamani P, Deep G, et al. Silibinin preferentially radiosensitizes prostate cancer by inhibiting DNA repair signaling. Mol Cancer Ther. 2015;14:2722–34.CrossRefPubMedPubMedCentral
24.
25.
Osipov AN, Pustovalova M, Grekhova A, et al. Low doses of X-rays induce prolonged and ATM-independent persistence of γH2AX foci in human gingival mesenchymal stem cells. Oncotarget. 2015;6:27275–87.CrossRefPubMedPubMedCentral
26.
Nakajima NI, Brunton H, Watanabe R, et al. Visualisation of γH2AX foci caused by heavy ion particle traversal; distinction between core track versus non-track damage. PLoS ONE. 2013;8:e70107.CrossRefPubMedPubMedCentral
27.
Keogh MC, Kim JA, Downey M, et al. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature. 2006;439:497–501.CrossRefPubMed
28.
MacPhail SH, Banáth JP, Yu TY, et al. Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol. 2003;79:351–8.CrossRefPubMed
29.
MacPhail SH, Banáth JP, Yu Y, et al. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res. 2003;159:759–67.CrossRefPubMed
30.
Yu T, MacPhail SH, Banáth JP, et al. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst). 2006;5:935–46.CrossRefPubMed
31.
Ismail IH, Wadhra TI, Hammarsten O. An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans. Nucleic Acids Res. 2007;35:e36.CrossRefPubMedPubMedCentral
32.
MacPhail SH, Banáth JP, Yu Y, et al. Cell cycle-dependent expression of phosphorylated histone H2AX: reduced expression in unirradiated but not X-irradiated G1-phase cells. Radiat Res. 2003;159:759–67.CrossRefPubMed
33.
Tanaka T, Kurose A, Halicka HD, et al. 2-deoxy-d-glucose reduces the level of constitutive activation of ATM and phosphorylation of histone H2AX. Cell Cycle. 2006;5:878–82.CrossRefPubMed
34.
Chen Z, Xiao Z, Gu WZ, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer. 2006;119:2784–94.CrossRefPubMed
Metadata
Title
pATM and γH2AX are effective radiation biomarkers in assessing the radiosensitivity of 12C6+ in human tumor cells
Authors
Jin Zhao
Zhong Guo
Shuyan Pei
Lei Song
Chenjing Wang
Jianxiu Ma
Long Jin
Yanqing Ma
Renke He
Jianbin Zhong
Ying Ma
Hong Zhang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0419-5

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

Growth of MCF-7 breast cancer cells and efficacy of anti-angiogenic agents in a hydroxyethyl chitosan/glycidyl methacrylate hydrogel

Primary Research

Inhibition of breast cancer cell proliferation and tumorigenesis by long non-coding RNA RPPH1 down-regulation of miR-122 expression

Primary Research

Down-regulation of IFITM1 and its growth inhibitory role in cervical squamous cell carcinoma

Primary Research

SNP rs3202538 in 3′UTR region of ErbB3 regulated by miR-204 and miR-211 promote gastric cancer development in Chinese population

Primary research

Establishment and characterization of a novel highly aggressive gallbladder cancer cell line, TJ-GBC2

Primary Research

Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits